March 2026 in “Journal of the American Academy of Dermatology” The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
Baricitinib works better than methotrexate for severe alopecia areata.
Wnt-activating drugs generally do not increase cancer risk.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
May 2024 in “Reactions weekly” September 2015 in “Photodiagnosis and Photodynamic Therapy” January 2017 in “ScholarWorks - WMU (Western Michigan University)” Stopping SSRIs can reverse hair loss in some patients.
6 citations
,
February 2021 in “Frontiers in Neurology” Cyclosporine-A can cause serious blood clots in the brain, so patients need careful monitoring.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
1 citations
,
October 2019 in “Epileptic disorders” A girl with Pitt-Hopkins syndrome developed curly hair as a rare side effect from the epilepsy drug perampanel.
June 2014 in “Reactions Weekly”
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
August 2011 in “Reactions Weekly” April 2015 in “Reactions Weekly” May 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly” January 2009 in “Reactions Weekly” January 2014 in “Reactions Weekly”
November 2025 in “Preprints.org” Phenytoin and spironolactone help prevent hair loss from chemotherapy by reducing stress and inflammation.
February 2008 in “Reactions Weekly” January 2004 in “Reactions Weekly” January 2023 in “Reactions Weekly”